Novo Nordisk
886.6 DKK +2.28%109 investors are following this company
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Revenue
232.26B
EBIT %
44.16 %
P/E
47.49
Dividend yield-%
1.06 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
NOVO B
Daily low / high price
867.3 / 886.6
DKK
Market cap
3.96T DKK
Turnover
1.84B DKK
Volume
2.1M
Latest videos
Financial calendar
Interim report
02.05.2024
Interim report
07.08.2024
Interim report
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo Holdings AS | 28.3 % | 76.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Vedtægter for Novo Nordisk, april 2024
Novo Nordisk A/S - Articles of Association, April 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools